These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1711363)
1. Vasculature as a target for anti-cancer therapy. Moore JV; West DC Cancer Cells; 1991 Mar; 3(3):100-2. PubMed ID: 1711363 [No Abstract] [Full Text] [Related]
2. Targeting the vasculature of solid tumours. Murray JC; Hewett PW; Martin SG QJM; 1996 Mar; 89(3):165-7. PubMed ID: 8731559 [No Abstract] [Full Text] [Related]
4. [Angiogenin-induced angiogenesis as a target in the therapy of tumors]. Komolova GS; Rustam'ian IuL Eksp Klin Farmakol; 1998; 61(5):81-4. PubMed ID: 9854643 [No Abstract] [Full Text] [Related]
5. Tumour blood flow: measurement and manipulation for therapeutic gain. Sagar SM; Klassen GA; Barclay KD; Aldrich JE Cancer Treat Rev; 1993 Oct; 19(4):299-349. PubMed ID: 7693345 [No Abstract] [Full Text] [Related]
6. The current status of targeting tumour vasculature as a means of cancer therapy: an overview. Denekamp J Int J Radiat Biol; 1991; 60(1-2):401-8. PubMed ID: 1713939 [No Abstract] [Full Text] [Related]
7. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Dvorak HF; Nagy JA; Dvorak AM Cancer Cells; 1991 Mar; 3(3):77-85. PubMed ID: 1711364 [TBL] [Abstract][Full Text] [Related]
8. Angiogenic attack as a therapeutic strategy for cancer. Denekamp J; Hill S Radiother Oncol; 1991; 20 Suppl 1():103-12. PubMed ID: 2020760 [No Abstract] [Full Text] [Related]
9. From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics. Weiner LM Cancer J; 2008; 14(3):147-8. PubMed ID: 18536553 [No Abstract] [Full Text] [Related]
10. Recombinant antibodies for the selective targeting of tumor neovasculature. Viti F; Giovannoni L; Neri D Curr Opin Drug Discov Devel; 2002 Mar; 5(2):204-13. PubMed ID: 11926127 [TBL] [Abstract][Full Text] [Related]
11. Antibody-based targeting of the tumor vasculature. Schliemann C; Neri D Biochim Biophys Acta; 2007 Dec; 1776(2):175-92. PubMed ID: 17920773 [TBL] [Abstract][Full Text] [Related]
13. Physiological effects of hyperthermia. Reinhold HS Recent Results Cancer Res; 1988; 107():32-43. PubMed ID: 3287521 [No Abstract] [Full Text] [Related]
14. Vascular targeting--a new approach to the therapy of solid tumors. Burrows FJ; Thorpe PE Pharmacol Ther; 1994 Oct; 64(1):155-74. PubMed ID: 7846113 [TBL] [Abstract][Full Text] [Related]
15. The use of hyperthermia within the frame of cancer multistep therapy. von Ardenne M; Krüger W Ann N Y Acad Sci; 1980; 335():356-61. PubMed ID: 6931529 [No Abstract] [Full Text] [Related]
16. The effect of therapy on tumour vascular function. Chaplin DJ Int J Radiat Biol; 1991; 60(1-2):311-25. PubMed ID: 1677988 [TBL] [Abstract][Full Text] [Related]
17. A monoclonal antibody (E-9) binds preferentially to the vasculatures of human tumors, embryonic and regenerating tissues. Wang JM; Hunter RD; Kumar S EXS; 1992; 61():266-71. PubMed ID: 1377542 [No Abstract] [Full Text] [Related]
18. Targeting angiogenesis with monoclonal antibodies. Bicknell R Ann Oncol; 2006 Sep; 17 Suppl 10():x76-8. PubMed ID: 17018756 [No Abstract] [Full Text] [Related]
19. Present status of biological response modifiers in cancer. Parkinson DR Am J Med; 1995 Dec; 99(6A):54S-56S. PubMed ID: 8585537 [No Abstract] [Full Text] [Related]
20. Antiangiogenesis for cancer therapy. Harris AL Lancet; 1997 May; 349 Suppl 2():SII13-5. PubMed ID: 9164441 [No Abstract] [Full Text] [Related] [Next] [New Search]